Tommy Stallings

Learn More
5005 Background: Recurrent ovarian cancer following treatment of advanced disease with platinum-based therapy, such as GC, is associated with poor prognosis and 5-year survival. Addition of iniparib(More)
5004 Background: GC is an established chemotherapy combination for patients with platinum-sensitive recurrent ovarian cancer, with an associated overall response rate (ORR) of 47.2% (Pfisterer et al.(More)
  • 1